Cognition Therapeutics (CGTX)
NASDAQ:CGTX
Want to see CGTX full AI Analyst Report?
Total Valuation
Cognition Therapeutics has a market cap or net worth of $102.03M. The enterprise value is $49.54M.
Market Cap$102.03M
Enterprise Value$49.54M
Share Statistics
Cognition Therapeutics has 89,498,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding89,498,020
Owned by Insiders17.43%
Owned by Institutions14.32%
Financial Efficiency
Cognition Therapeutics’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -136.92%.
Return on Equity (ROE)-0.69
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-136.92%
Return on Capital Employed (ROCE)-1.39
Revenue Per Employee0.00
Profits Per Employee-939.48K
Employee Count25
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cognition Therapeutics is ―. Cognition Therapeutics’s PEG ratio is 0.07.
PE Ratio―
PS Ratio0.00
PB Ratio2.87
Price to Fair Value2.87
Price to FCF-4.00
Price to Operating Cash Flow-5.02
PEG Ratio0.07
Income Statement
In the last 12 months, Cognition Therapeutics had revenue of 0.00 and earned -23.49M in profits. Earnings per share was -0.32.
Revenue0.00
Gross Profit0.00
Operating Income-47.80M
Pretax Income-23.49M
Net Income-23.49M
EBITDA-23.25M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -20.25M and capital expenditures 0.00, giving a free cash flow of -20.25M billion.
Operating Cash Flow-20.25M
Free Cash Flow-20.25M
Free Cash Flow per Share-0.23
Dividends & Yields
Cognition Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.75
52-Week Price Change245.45%
50-Day Moving Average1.03
200-Day Moving Average1.37
Relative Strength Index (RSI)62.42
Average Volume (3m)2.91M
Important Dates
Cognition Therapeutics upcoming earnings date is Aug 11, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Cognition Therapeutics as a current ratio of 3.45, with Debt / Equity ratio of 1.55%
Current Ratio3.45
Quick Ratio3.45
Debt to Market Cap<0.01
Net Debt to EBITDA1.56
Interest Coverage Ratio-3.68K
Taxes
In the past 12 months, Cognition Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cognition Therapeutics EV to EBITDA ratio is -2.67, with an EV/FCF ratio of -2.52.
EV to Sales0.00
EV to EBITDA-2.67
EV to Free Cash Flow-2.52
EV to Operating Cash Flow-2.52
Balance Sheet
Cognition Therapeutics has $31.13M in cash and marketable securities with $465.00K in debt, giving a net cash position of $30.66M billion.
Cash & Marketable Securities$31.13M
Total Debt$465.00K
Net Cash$30.66M
Net Cash Per Share$0.34
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cognition Therapeutics is $3.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.50
Price Target Upside194.12% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast64.57%